Assessing Lyophilization Process Levers to Ensure Robust Process Strategy in ADC Drug Product Manufacturing - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Assessing Lyophilization Process Levers to Ensure Robust Process Strategy in ADC Drug Product Manufacturing

2:30 pm - Wednesday 14th October 2026

Understanding the challenges to ensure consistent product quality in ADC lyophilization and DP manufacturing
Breaking down strategy to utilize lyophilization process levers to control factors across depyrogenation, nucleation and annealing
Laying out lessons for other ADC developers to approach lyophilization and DP manufacturing with confidence

Speakers:

Paritosh Pande

Paritosh Pande

Associate Principal Scientist, Sterile Drug Product Commercialization

Merck & Co